Novo Nordisk Told to Increase Indian Patient Enrollment for Ziltivekimab Study
Written By : Dr. Divya Colin
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-06-19 14:06 GMT | Update On 2025-06-19 14:06 GMT
Advertisement
New Delhi: In response to a proposal by Novo Nordisk, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended increasing the number of Indian subjects from 700 to 1000 in the Ziltivekimab C 30 mg/mL/placebo study, conducted under Protocol No. EX6018-4979.
The recommendation was made during the SEC (Cardiovascular) meeting held on 5th June 2025, after the company presented its updated proposal requesting an increase in the number of subjects from India 700 to 1000 protocol no. EX6018-4979.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.